CD30 e-Monograph

	The Role of CD30: New Frontiers in Targeting Therapy for Malignant Lymphomas CME, CPE, CNE Anton Hagenbeek, MD, PhD – Activity Chair; Tim Illidge, PhD, MRCP, FRCR, FRCPath; Anas Younes, MD
	Release Date: October 21, 2016 Expiration Date: October 21, 2017
	The rapid pace of scientific advances in lymphoma research makes it challenging for clinicians to stay up-to-date on the latest treatment options and ongoing clinical trials. To meet this challenge, a panel of lymphoma experts has provided the latest information on current and future developments in the treatment of CD30+ lymphomas and on novel therapeutic options that target CD30 in HL. Summaries of recent clinical trials studying CD30-targeted therapy in other lymphoma subtypes will address safety and efficacy data in these diseases. Provided by MediCom Worldwide, Inc. This activity is supported by an educational grant from Takeda Oncology
	View Only, CE Expired View Only, No Credit

	Key Issues in the Treatment of Lymphoma: The Role of CD30 in Diagnosis and Management CME, CPE, CNE Anton Hagenbeek, MD, PhD – Program Chair; Francesco d’Amore, MD; Stefano Pileri, MD; Anas Younes, MD
	Release Date: September 30, 2015 Expiration Date: September 30, 2016
	With the advances made in frontline multiagent chemotherapy, Hodgkin lymphoma (HL) is deemed to be a highly curable disease. Nonetheless, advanced HL remains a challenge as 10% of patients will not achieve a complete remission and 20–30% of patients who initially responded will experience a relapse. This activity brings together leading world experts in lymphoma to discuss some of the most talked about issues and ongoing clinical trials in the treatment of HL today. Provided by MediCom Worldwide, Inc. This activity has been supported by an educational grant from Takeda Oncology. MediCom Worldwide, Inc. acknowledges support from The Leukemia & Lymphoma Society
	View Only, CE Expired View Only, No Credit